University of Texas Health Science Center at Houston

UTHealth joins trial of arthritis drug’s effect on COVID-19-induced cytokine storm

Newswise — A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

The Phase III, multisite, randomized, double-blind, placebo-controlled study is evaluating the effectiveness of the drug canakinumab, an interleukin-1 (IL-1) blocker approved for the treatment of juvenile rheumatoid arthritis, for preventing cytokine release syndrome (CRS) in COVID-19 patients with pneumonia.

Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once. Cytokines include a broad category of proteins secreted by the body. IL-1 serves as the first-line defense for the immune system, alerting other proteins to respond if a virus or bacteria are present.

Canakinumab blocks the production of IL-1 protein, which could prevent a possible deadly overreaction of the immune system in COVID-19 patients. Research has linked a number of COVID-19 deaths to CRS due to damage caused to several major organs.

The COVID-19 pandemic has reminded researchers at UTHealth of the early days of the HIV pandemic, when confusion and fear affected many communities and few treatment options were available.

Roberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease with McGovern Medical School at UTHealth, said this is a time for the HIV research community to utilize members’ expertise in the search for a treatment for the coronavirus. Arduino’s research background includes the study of new antiretroviral drugs, treatment strategies, immune activation, and inflammation in the search of a HIV cure.

“The research community truly feels compelled to do something in the search for a viable treatment for COVID-19, and I feel I owe it to my community to offer my expertise,” said Arduino, who has led HIV clinical research for 22 years.

Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with COVID-19-induced pneumonia. Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight; or placebo. All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.

Novartis Pharmaceuticals and the National Institutes of Health AIDS Clinical Trials Network are sponsoring this clinical trial. For more information, visit ClinicalTrials.gov.



Filters close

Showing results

110 of 6112
Newswise: New Study Details Enzyme That Allows Coronavirus to Resist Antiviral Medications
Released: 3-Aug-2021 12:20 PM EDT
New Study Details Enzyme That Allows Coronavirus to Resist Antiviral Medications
Iowa State University

A new Iowa State University study details the structure of a critical enzyme present in SARS-CoV-2, the coronavirus that causes COVID-19. This enzyme removes nucleoside antiviral medications from the virus’s RNA, rendering many treatments ineffective. Scientists could use data uncovered in the new study to find ways to inhibit the enzyme, possibly leading to more effective treatments.

Released: 2-Aug-2021 6:05 PM EDT
Rethinking Remdesivir
University of California San Diego Health

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.

Newswise: Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Released: 2-Aug-2021 4:25 PM EDT
Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Hackensack Meridian Health

New COVID-19 40-day mortality risk model, published in The Public Library of Science ONE, has potential for use in patient treatment planning, comparisons of therapeutic strategies, and public-health preparations.

Released: 2-Aug-2021 4:05 PM EDT
Town Hall on Effectiveness of COVID-19 Vaccination in Immunosuppressed Patients Hosted by the American College of Rheumatology
American College of Rheumatology (ACR)

How effective COVID-19 vaccines have been in immunosuppressed and rheumatic disease patients remains an incompletely answered question. The American College of Rheumatology (ACR) has organized an expert panel to share what we are learning from real-world data and answer questions.

Released: 2-Aug-2021 2:00 PM EDT
CDC withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test does not mean the test failed
Newswise

Social media is now rife with claims about why the CDC is withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test after December 2021.

Newswise: Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Released: 2-Aug-2021 1:30 PM EDT
Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Argonne National Laboratory

Scientists using the Advanced Photon Source have discovered that a drug used to fight tumors in animals might be effective against many types of coronaviruses, including SARS-CoV-2.

Released: 2-Aug-2021 11:25 AM EDT
Award-Winning Journalist and CDC Principal Investigator to Serve as ACR Convergence 2021 Keynote Speaker
American College of Rheumatology (ACR)

Convergence 2021, the annual meeting of the American College of Rheumatology (ACR), returns to a virtual meeting platform Nov. 1 - 10. This year’s meeting will include presentations from over 320 clinicians, researchers and health experts, including this year’s keynote speaker, Dr. Seema Yasmin.

Newswise: COVID-19: Small Sign of Hope as Vaccinations Rise
Released: 2-Aug-2021 10:45 AM EDT
COVID-19: Small Sign of Hope as Vaccinations Rise
Cedars-Sinai

As COVID-19 cases spike in Los Angeles and throughout the Golden State, driven by the spread of the delta variant among unvaccinated residents, there may be a small sign of hope: More people are finally getting their shot.

Newswise: New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
Released: 31-Jul-2021 10:05 AM EDT
New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
University of Miami Health System, Miller School of Medicine

The University’s coronavirus sequencing effort uncovered that there are several variants present in its patient population, but Delta is chief among them and easily transmitted. And its presence is likely triggering a local surge in the infectious disease. University of Miami researchers and physicians are seeing firsthand how rapidly the Delta variant of COVID-19 is spreading through the local population.


Showing results

110 of 6112

close
1.94967